Ginkgetin Ameliorates Neuropathological Changes in APP/PS1 Transgenical Mice Model

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) pathogenesis involves amyloid beta (Aβ) accumulation, gliosis, and cerebral amyloid angiopathy (CAA).
• Ginkgetin, a Ginkgo biloba biflavone, demonstrates neuroprotective effects against oxidative stress and Aβ toxicity in vitro.
• The in vivo therapeutic efficacy of ginkgetin for Alzheimer's disease remains largely unexplored.

Purpose of the Study:

• To investigate the therapeutic effects of a 9-month ginkgetin diet in APP/PS1 transgenic mice, an established model for Alzheimer's disease.

Main Methods:

• Administration of a ginkgetin-supplemented diet to APP/PS1 transgenic mice for nine months.
• Quantification of plasma Aβ levels.
• Assessment of Aβ plaque burden in the brain.
• Evaluation of cerebral microhemorrhage incidence.
• Measurement of astrogliosis and inflammatory markers.

Main Results:

• Ginkgetin significantly reduced plasma Aβ levels by 59% and brain Aβ plaques by 51% (P<0.05).
• Treatment effectively inhibited cerebral microhemorrhage by 69% (P<0.05).
• Ginkgetin significantly decreased astrogliosis by 50% and ameliorated neuroinflammation (P<0.05).

Conclusions:

• Ginkgetin exhibits significant therapeutic properties beneficial for Alzheimer's disease.
• The study demonstrates ginkgetin's efficacy in reducing key pathological hallmarks of AD in vivo.
• Ginkgetin represents a potential therapeutic agent for managing Alzheimer's disease progression.